secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060486
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health reports Q1 net loss down 29% YoY; raises $4M in May offering
-------------------------------------------------------------------------

- Q1 revenue $334K (-11% YoY), net loss $1.5M vs $2.1M, operating expenses down 26%.
- Gross margin improved to 50% from 30%; gross profit up 48% to $167K.
- May 13 public offering: 4.71M shares + warrants at $0.85/share, gross $4M, net $3.5M.
- Clinical study with Feinstein Institutes showed ncVNS induced autonomic and neurologic responses equivalent to implanted devices.
- Launched ClearUP 2.0; exclusive distribution deal with top-10 distributor for Walmart, Target, Kroger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024060486/0000950170-24-060486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024060486/tivc-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer